HK Stock Market Move | ASCLETIS-B(01672) increased by more than 8%. The new drug clinical trial application for ASC47 in combination with Simcereglutide has been approved by the US FDA.

ASCLETIS-B(01672) rose by over 8%, reaching a 8.03% increase to 7.94 Hong Kong dollars, with a trading volume of 17.691 million Hong Kong dollars as of the time of reporting. In terms of news, GeneScience Pharmaceuticals announced this morning that exciting pharmacokinetic and weight loss data have been obtained from a single subcutaneous injection study (NCT06427590) of ASC47 in healthy subjects with elevated low-density lipoprotein cholesterol (LDL-C) (Part 1) and obese patients (Part 2). The company stated that the investigational new drug application (IND) for a Phase 1 clinical trial of ASC47 in combination with semaglutide for the treatment of obesity has recently been approved by the US Food and Drug Administration (FDA), with the first patient dosing expected to be completed by the end of the second quarter of 2025. ASC47 is a candidate drug for the targeted treatment of obesity with a focus on reducing weight without muscle loss. China Securities Co., Ltd. Securities pointed out that the global weight loss drug market is experiencing robust growth, with many overweight or obese adults in need of innovative drugs to improve their quality of life. In this context, the company's two drugs ASC30 and ASC47 have differentiated design approaches, making their future product development promising.